RTW Biotech portfolio company Yarrow Bioscience completes merger

Hemogenyx partners with Lithuanian cancer centre on HG-CT-1 research and clinical programme

Evinova and Merck KGaA partner to accelerate AI-driven clinical development

WuXi Biologics gains FTSE4Good recognition for sixth consecutive year

Lantern Pharma advances EMA-cleared Phase 1b/2 bladder cancer trial for LP-184

DifGen Pharmaceuticals' single injection treatment for advanced breast cancer cleared for clinical development

AbelZeta's C-CAR168 registrational Phase II trial in refractory Lupus Nephritis granted FDA clearance

CSL reports positive top-line Phase 3b results for ANDEMBRY (garadacimab-gxii) in children with HAE

Yarrow Bioscience completes VYNE merger and begins Phase 2 trial of YB-101

Harbour BioMed and Sinopharm establish innovation R&D consortium

argenx agrees to acquire Forte Biosciences for USD2.2bn to add anti-CD122 antibody FB102

AstraZeneca reports positive Phase III survival results for Sone-Ve in advanced gastric cancers

Faron reports encouraging first overall survival data from BEXMAB frontline HR-MDS trial

NewAmsterdam Pharma and Menarini Group report positive CHMP opinion for obicetrapib monotherapy and obicetrapib/ezetimibe combination

CHMP backs Gilead's Trodelvy-Keytruda combination for first-line metastatic triple-negative breast cancer